N. Androulakis

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

John Souglakos, N. Androulakis, K. Syrigos et al. · British Journal of Cancer · 2006 · 399 citations · Full text

Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy

John Souglakos, A. Kalykaki, L. Vamvakas et al. · Annals of Oncology · 2006 · 63 citations

Oncology, Phase Ii Trial, Gastrointestinal Oncology +8

Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI Regimen) as First Line Treatment for Elderly Patients with Metastatic Colorectal Cancer: A Phase II Trial

John Souglakos, Athanasios Pallis, Stylianos Kakolyris et al. · Oncology · 2005 · 62 citations

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial

Zenia Saridaki, N. Androulakis, N. Vardakis et al. · British Journal of Cancer · 2012 · 56 citations · Full text

First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study

Pavlos Papakostas, Ch. Kouroussis, N. Androulakis et al. · European Journal of Cancer · 2001 · 52 citations

Surgical Oncology, Gastrointestinal Oncology, Biliary Tract +10